PROK
ProKidney Corp
$
2.495
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.585
Open
2.560
VWAP
2.54
Vol
294.17K
Mkt Cap
758.10M
Low
2.490
Amount
746.26K
EV/EBITDA(TTM)
--
Total Shares
121.84M
EV
1.80B
EV/OCF(TTM)
--
P/S(TTM)
--
ProKidney Corp. is a clinical-stage cellular therapeutics company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. It is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.144
-9.69%
--
--
-0.143
+2.28%
--
--
-0.153
-10.27%
Estimates Revision
The market is revising No Change the revenue expectations for ProKidney Corp. (PROK) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 232.67%.
EPS Estimates for FY2025
Revise Downward
-4.95%
In Past 3 Month
Stock Price
Go Up
+232.67%
In Past 3 Month
6 Analyst Rating
124.45% Upside
Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 5.60 USD with a low forecast of 1.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
1 Sell
Moderate Buy
124.45% Upside
Current: 2.495
Low
1.00
Averages
5.60
High
9.00
124.45% Upside
Current: 2.495
Low
1.00
Averages
5.60
High
9.00
UBS
Buy
upgrade
$4 -> $8
2025-07-15
Reason
UBS
Price Target
$4 -> $8
2025-07-15
upgrade
Buy
Reason
UBS raised the firm's price target on ProKidney to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.
Guggenheim
Buy
maintain
$6 -> $7
2025-07-14
Reason
Guggenheim
Price Target
$6 -> $7
2025-07-14
maintain
Buy
Reason
Guggenheim raised the firm's price target on ProKidney to $7 from $6 and keeps a Buy rating on the shares. Guggenheim says it was "very surprised" by the move in ProKidney shares last week following an "encouraging but somewhat incremental" data release on Tuesday from the rilparencel Phase 2 REGEN-007 trial, and tells investors in a research note that the firm was surprised by the enthusiasm experts showed for rilparencel following this data update. The firm awaits next month's regulatory update after the company's Type B Meeting with the FDA, and the full REGEN-007 data presentation at the American Society of Nephrology Meeting in November.
Citi
Buy
upgrade
$6 -> $9
2025-07-08
Reason
Citi
Price Target
$6 -> $9
2025-07-08
upgrade
Buy
Reason
Citi raised the firm's price target on ProKidney to $9 from $6 and keeps a Buy rating on the shares after the company reported results from the Phase 2 REGEN-007 study evaluating rilparencel in diabetes and chronic kidney disease. The firm says the initial data exceeded Citi's and management's expectations. REGEN-007 demonstrated statistically significant efficacy in group one, which may support accelerated approval in Phase 3 pending FDA confirmation, the analyst tells investors in a research note. Citi upped its probability of sucess for REGEN-007 to 60% from 50%.
BofA
Jason Gerberry
Neutral -> Underperform
downgrade
$3 -> $1
2025-06-30
Reason
BofA
Jason Gerberry
Price Target
$3 -> $1
2025-06-30
downgrade
Neutral -> Underperform
Reason
BofA analyst Jason Gerberry downgraded ProKidney to Underperform from Neutral with a price target of $1, down from $3.
BofA
Neutral -> Underperform
downgrade
$3 -> $1
2025-06-30
Reason
BofA
Price Target
$3 -> $1
2025-06-30
downgrade
Neutral -> Underperform
Reason
BofA downgraded ProKidney to Underperform from Neutral with a price target of $1, down from $3. The downgrade reflects more conservative peak sales for REACT, the company's sole product candidate in development for treatment of diabetic chronic kidney disease, the analyst tells investors in a research note. Recent discussions with nephrology experts suggest changes in the competitive landscape and the REACT program, warranting more segmentation-related "haircuts" and reducing the total addressable market, the firm says. The risk/reward skews to the downside with a financing overhang and limited value-inflection catalysts, BofA argues.
JP Morgan
Anupam Rama
Hold
Initiates
n/a
2024-09-30
Reason
JP Morgan
Anupam Rama
Price Target
n/a
2024-09-30
Initiates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for ProKidney Corp (PROK.O) is -4.55, compared to its 5-year average forward P/E of -5.49. For a more detailed relative valuation and DCF analysis to assess ProKidney Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.49
Current PE
-4.55
Overvalued PE
-0.35
Undervalued PE
-10.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.49
Current EV/EBITDA
-7.80
Overvalued EV/EBITDA
-2.54
Undervalued EV/EBITDA
-10.43
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
108.85
Current PS
2503.93
Overvalued PS
630.22
Undervalued PS
-412.53
Financials
Annual
Quarterly
FY2025Q1
230.00K
Total Revenue
FY2025Q1
YoY :
+3.27%
-41.39M
Operating Profit
FY2025Q1
YoY :
+7.41%
-37.95M
Net Income after Tax
FY2025Q1
YoY :
-18.75%
-0.13
EPS - Diluted
FY2025Q1
YoY :
-13.70%
-30.73M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-16.50K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
312.5K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
41.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
7
1.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
312.5K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
41.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
7
1.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PROK News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
07:32:05
ProKidney announces alignment with FDA on rilparencel accelerated approval path
2025-07-08 (ET)
2025-07-08
15:34:02
ProKidney move after REACT update 'looks overdone,' says BofA
2025-07-08
07:10:06
ProKidney reports statistically significant results for Phase 2 REGEN-007 trial
Sign Up For More Events
Sign Up For More Events
News
4.0
07-20Yahoo FinanceJP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
9.0
07-15NASDAQ.COMProKidney Secures FDA Alignment On Accelerated Approval Pathway For Rilparencel
2.0
07-15BenzingaSimulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Sign Up For More News
People Also Watch
ACCO
ACCO Brands Corp
3.660
USD
+0.55%
CHPT
ChargePoint Holdings Inc
10.914
USD
-1.41%
CBNK
Capital Bancorp Inc
31.250
USD
-0.89%
CCSI
Consensus Cloud Solutions Inc
24.120
USD
+1.17%
ANAB
AnaptysBio Inc
20.150
USD
-4.18%
BIGC
Bigcommerce Holdings Inc
4.810
USD
0.00%
INNV
InnovAge Holding Corp
3.310
USD
0.00%
CPAC
Cementos Pacasmayo SAA
6.240
USD
-0.08%
XERS
Xeris Biopharma Holdings Inc
7.290
USD
+6.58%
GDOT
Green Dot Corp
9.740
USD
+1.04%
FAQ
What is ProKidney Corp (PROK) stock price today?
The current price of PROK is 2.495 USD — it has decreased -3.67 % in the last trading day.
What is ProKidney Corp (PROK)'s business?
What is the price predicton of PROK Stock?
What is ProKidney Corp (PROK)'s revenue for the last quarter?
What is ProKidney Corp (PROK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ProKidney Corp (PROK)'s fundamentals?
How many employees does ProKidney Corp (PROK). have?